腾盛博药(BRII-B)宣布了其针对慢性乙型肝炎治疗的2b期Enrich和Enhance研究在治疗结束时的顶线数据结果。该数据揭示了相关治疗方案在关键研究节点上的初步表现,为公司后续的临床开发决策提供了重要依据。
腾盛博药(BRII-B)宣布了其针对慢性乙型肝炎治疗的2b期Enrich和Enhance研究在治疗结束时的顶线数据结果。该数据揭示了相关治疗方案在关键研究节点上的初步表现,为公司后续的临床开发决策提供了重要依据。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.